In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: Poor efficacy of posaconazole

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2246-2250

  Salas, Valentina ^a   Pastor, F Javier ^a   Calvo, Enrique ^a   Alvarez, Eduardo ^a   Sutton, Deanna A ^b   Mayayo, Emilio ^a   Fothergill, Anette W ^b   Rinaldi, Michael G ^b   Guarro, Josep ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; POSACONAZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; DISK DIFFUSION; DRUG EFFICACY; IN VITRO STUDY; IN VIVO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MUCOR; MUCOR CIRCINELLOIDES; MUCORMYCOSIS; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BRAIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, FUNGAL; KIDNEY; MALE; MICE; MICROBIAL SENSITIVITY TESTS; MUCOR; MUCORMYCOSIS; NEUTROPENIA; SPECIES SPECIFICITY; SURVIVAL RATE; TREATMENT FAILURE; TRIAZOLES;

EID: 84860115196     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05956-11     Document Type: Article

References (29)

1. Alastruey-Izquierdo A, et al. 2009. Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. Antimicrob. Agents Chemother. 53:1686-1689.
2. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. 2007. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob. Agents Chemother. 51:2587-2590. (Pubitemid 47047341)
3. Alvarez E, et al. 2009. Spectrum of zygomycetes species identified in clinically significant specimens in the United Stated. J. Clin. Microbiol. 47:1650-1656.
4. Alvarez E, et al. 2011. Two new species of Mucor from clinical samples. Med. Mycol. 49:62-72.
5. Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P. 2008. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med. Mycol. 46:567-573.
6. Balajee SA, et al. 2009. Sequence-based identification of Aspergillus, Fusarium, and Mucorales species in the clinical mycology laboratory: where are we and where should we go from here? J. Clin. Microbiol. 47:877-884.
7. Chayakulkeeree M, Ghannoum MA, Perfect JR. 2006. Zygomycosis: the re-emerging fungal infection. Eur. J. Microbiol. Infect. Dis. 25:215-229. (Pubitemid 43800540)
8. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard, 2nd ed. Document M38-A2. CLSI, Wayne, PA.
9. Clinical and Laboratory Standards Institute. 2010. Method for antifungal disk diffusion susceptibility testing of nondermatophyte filamentous fungi. Approved guideline. Document M51-A. CLSI, Wayne, PA.
10. Clinical and Laboratory Standards Institute. 2009. Performance standards for antifungal disk diffusion susceptibility testing of filamentous fungi; informational supplement. Document M51-S1 (proposed). CLSI, Wayne, PA.
11. Dannaoui E, García-Hermoso D. 2007. The zygomycetes, p 159-183. In Kavanagh K (ed), New insights in fungal pathogenicity. Springer Science, Dordrecht, the Netherlands.
12. Dannaoui E, Meis JF, Loebenberg D, Verweij PE. 2003. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob. Agents Chemother. 47:3647-3650. (Pubitemid 37345740)
13. Espinel-Ingroff A. 2003. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12.052 fungal isolate: review of the literature. Rev. Iberoam. Micol. 20:121-136. (Pubitemid 38724618)
14. Espinel-Ingroff A. 2006. Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B. J. Clin. Microbiol. 44:3616-3622. (Pubitemid 46768814)
15. Espinel-Ingroff A, Chaturvedi V, Fothergill A, Rinaldi MG. 2002. Optimal testing conditions for determining MICs and minimum fungicidal concentration of new and established antifungal agents for uncommon moulds: NCCLS collaborative study. J. Clin. Microbiol. 40:3776-3781.
16. Graybill JR. 2000. The role of murine models in the development of antifungal therapy for systemic mycoses. Drug Resist. Updat. 3:364-383. (Pubitemid 32118402)
17. Guarro J. 2011. Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi. J. Antimicrob. Chemother. 66:1447-1466.
18. Khan ZU, Ahmad S, Brazda A, Chandy R. 2009. Mucor circinelloides as a cause of invasive maxillofacial zygomycosis: an emerging dimorphic pathogen with reduced susceptibility to posaconazole. J. Clin. Microbiol. 47:1244-1248.
19. Larché J, et al. 2005. Diagnosis of cutaneous mucormycosis due to Rhizopus microsporus by an innovative PCR-restriction fragment-length polymorphism method. Clin. Infect. Dis. 41:1362-1365. (Pubitemid 41532688)
20. Messer SA, et al. 2007. Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi. J. Antimicrob. Microbiol. 45:1322-1324. (Pubitemid 46626507)
21. Ortoneda M, Capilla J, Pastor FJ, Serena C, Guarro J. 2004. Interaction of granulocyte colony-stimulating factor and the high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis. Diagn. Microbiol. Infect. Dis. 50:247-251. (Pubitemid 39593147)
22. Pastor FJ, et al. 2010. In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. Antimicrob. Agents Chemother. 54: 4550-4555.
23. Ribes JA, Vanover-Sams CL, Baker DJ. 2000. Zygomycetes in human disease. Clin. Microbiol. Rev. 13:236-301. (Pubitemid 30205427)
24. Rodríguez MM, et al. 2010. Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. Antimicrob. Agents Chemother. 54:1665-1669.
25. Rodríguez MM, et al. 2009. Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. Antimicrob. Agents Chemother. 53:5022-5025.
26. Spellberg B, Jonh E, Jr, Ibrahim A. 2005. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin. Microbiol. Rev. 18:556-569. (Pubitemid 40995116)
27. Spreghini E, Orlando F, Giannini D, Barchiesi F. 2010. In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility. J. Antimicrob. Chemother. 65:2158-2163.
28. Sun QN, Fothergill AW, McCarthy DJ, Rinaldi MG, Graybill JR. 2002. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob. Agents Chemother. 46:1581-1582. (Pubitemid 34415351)
29. Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. 2002. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob. Agents Chemother. 46:2310-2312. (Pubitemid 34665939)